EMA Authorised: Kanuma (sebelipase alfa) — Alexion Europe SAS

View source ↗

Summary

The EMA authorised Kanuma (sebelipase alfa) for an inborn error of lipid metabolism. It was granted orphan medicine status with accelerated assessment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lysosomal Acid Lipase Deficiency

Drugs mentioned

• KANUMA (Sebelipase alfa)

Snippet

Status: Authorised. Therapeutic area: Lipid Metabolism, Inborn Errors. MAH: Alexion Europe SAS. Decision date: 24/03/2026. Orphan medicine. Accelerated assessment